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These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV1) profile of once-daily (QD) olodaterol
compared to placebo and twice-daily (BID) formoterol in patients with moderate to very severe chronic obstructive
pulmonary disease. In two replicate, randomized, double-blind, double-dummy, four-way crossover studies,
patients received olodaterol 5 and 10 μg QD, formoterol 12 μg BID, or placebo for 6 weeks in addition to
usual-care background maintenance therapy. Co-primary end points were FEV1 area under the curve from 0–12 h
(AUC0–12) response (change from baseline) and FEV1 AUC from 12–24 h (AUC12–24) response after 6 weeks, with FEV1
AUC from 0–24 h response identified as a key secondary end point. Other secondary end points included FEV1 AUC
from 0–3 h and trough FEV1 responses, as well as corresponding forced vital capacity responses. With both olodaterol
doses, FEV1 increased to near-maximal 30 min post-morning dose, which was sustained over 24 h. FEV1 also increased
within 30 min post-morning dose of formoterol and was sustained over 12 h; the second formoterol dose resulted in a
further increase, sustained for an additional 12 h. FEV1 AUC0–12 and AUC12–24 responses with both QD olodaterol doses
and BID formoterol were significantly greater than placebo at 6 weeks (P < .0001). Secondary end-point outcomes
were consistent with those of the co-primary end points. These data, together with those from the wider phase III
clinical program, provide evidence for the 24-h bronchodilator efficacy of olodaterol QD in this patient population.
Trial registry: ClinicalTrials.gov; NCT00931385 and NCT00932646.Introduction
Long-acting bronchodilators, such as long-acting β2-
agonists (LABAs) and long-acting muscarinic antago-
nists, are the cornerstone of pharmacologic therapy for
patients with chronic obstructive pulmonary disease
(COPD) and are considered central to symptom manage-
ment (Global Initiative for Chronic Obstructive Lung
Disease 2013). The first long-acting bronchodilators
available for maintenance treatment of COPD were
the LABAs salmeterol and formoterol, which had a <24-h
duration of action and so required twice-daily (BID)* Correspondence: gfeld3232@aol.com
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in any medium, provided the original work is pdosing (Global Initiative for Chronic Obstructive Lung
Disease 2013). The development of newer LABAs, such
as indacaterol, with a longer 24-h duration of action
(Rodrigo & Neffen 2012) allows for a once-daily (QD)
posology (Toy et al. 2011).
Olodaterol is a LABA (Bouyssou et al. 2010a) with
high β2-receptor selectivity and a near full agonist re-
sponse at the human β2-adrenoceptor (Bouyssou et al.
2010b). Effective 24-h bronchodilation with olodaterol in
both asthma and COPD has been confirmed by single-
dose studies (van Noord et al. 2011; O’Byrne et al. 2009)
and studies over 4 weeks (Joos et al. 2012; O’Byrne
et al. 2012; van Noord et al. 2009). The results of these
phase II studies provided the rationale to further investi-
gate 5 and 10 μg QD doses of olodaterol in a phase III
clinical program.s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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gram was designed to evaluate multiple efficacy and
safety end points in five sets of paired studies that be-
tween them assessed 48-week lung-function efficacy,
symptomatic benefit, 24-h bronchodilator profile, and
exercise capacity. All studies were conducted in replicate
to independently authenticate outcomes (US Department
of Health and Human Services et al. 1998).
The primary objective of the replicate studies pre-
sented here was to determine the 24-h forced expiratory
volume in 1 sec (FEV1) profile of olodaterol 5 and 10 μg
QD in comparison to placebo and formoterol 12 μg BID
in patients with moderate to very severe (Global initia-
tive for chronic Obstructive Lung Disease stage 2–4)
COPD. Formoterol was chosen as the active comparator
because QD LABAs were not available at the time these
studies were conducted. These studies are complemen-
tary to two replicate pivotal studies that, as a secondary
end point, measured FEV1 responses over 12 h in a
subset of patients (NCT00782210 and NCT00782509)
(Ferguson et al. 2013) and two replicate 6-week studies
(NCT01040689 and NCT01040728) that assessed the 24-h
profile of olodaterol QD vs tiotropium (Lange et al. 2013).
In the studies presented here, the study population
was chosen to allow evaluation of the 24-h bronchodilation
activity of olodaterol in patients closely representative of
those in clinical practice, with specific attention given to
disease severity, co-morbidities, and background therapies
(European Medicines Agency 2012).
Methods
Study design
These were replicate, multicenter, randomized, double-
blind, double-dummy, placebo-controlled, four-way
crossover studies (registered with ClinicalTrials.gov:
NCT00931385 [study 1222.24] and NCT00932646 [study






Crossover study – 4 treatments given in ra
formoterol BID; placebo QD 
Treatment 2
Figure 1 Study design. BID = twice daily; QD = once daily.who successfully completed a 2- to 6-week run-in period
to ensure clinical stability received each of the following
treatments in a random sequence: olodaterol 5 μg QD,
olodaterol 10 μg QD, formoterol 12 μg BID, and pla-
cebo. Each administration of olodaterol comprised two
actuations of the Respimat® inhaler QD, while formo-
terol was administered via Aerolizer® with each adminis-
tration comprising one actuation BID. Each treatment
period lasted for 6 weeks, with a 14-day washout in be-
tween. Patients were evaluated for 14 days following
study completion. With the exception of LABAs, patients
continued usual-care background COPD maintenance
treatment, including short-acting muscarinic antagonists,
long-acting muscarinic antagonists, inhaled corticoste-
roids, and xanthines, throughout the duration of these
trials. Patients on LABAs were allowed to switch to short-
acting muscarinic antagonists. Salbutamol (100 μg) was
provided to all patients as rescue medication.
The study was approved by local ethics committees and
carried out according to the Declaration of Helsinki and
local regulations. Prior to study initiation, the protocol was
approved by the local Institutional Review Board, Inde-
pendent Ethics Committee, and the Competent Authority.
All patients provided written, informed consent prior to
the study commencing. Details of the local Institutional
Review Boards are provided in Additional file 1: Table S1.
Patients
Patients were enrolled into the study if they met the
following inclusion criteria: aged ≥40 years; current
or ex-smokers with a smoking history of >10 pack-
years; post-bronchodilator FEV1 < 80% of predicted
normal; and post-bronchodilator FEV1/forced vital cap-
acity (FVC) <70%. Key exclusion criteria were: significant
disease other than COPD (defined by the investigator as
a disease that may put the patient at risk by participating
in the study, influence study outcomes, or cause concernEnd of 6-week treatment period
ndom order: olodaterol 5 µg QD; olodaterol 10 µg QD; 
Treatment 3 Treatment 4
Feldman et al. SpringerPlus 2014, 3:419 Page 3 of 10
http://www.springerplus.com/content/3/1/419with regards to the patient’s ability to participate in the
study); history of asthma; history of myocardial infarction
within 1 year of the screening visit; and unstable or life-
threatening cardiac arrhythmia within the past year.
Study outcomes
The primary objective of the study was to determine if
olodaterol 5 and 10 μg QD administered via the Respimat®a)
b)
Figure 2 CONSORT diagram illustrating participant flow in (a) study 1
who completed 4 treatment periods.inhaler provided superior 24-h bronchodilation vs placebo.
A secondary objective was to compare the 24-h FEV1
time profile of QD olodaterol with that of BID formo-
terol. Co-primary end points were FEV1 area under the
curve from 0 to 12 h (AUC0–12) response (defined as
change from study baseline) and FEV1 AUC from 12 to
24 h (AUC12–24) response after 6 weeks of treatment.
FEV1 AUC from 0 to 24 h (AUC0–24) response was222.24 and (b) study 1222.25. AE = adverse event. aAll patients
Table 1 Baseline patient demographics and disease
characteristics (treated set)
Study 1222.24 Study 1222.25
(n = 99) (n = 100)
Sex, n (%)
Male 52 (52.5) 54 (54.0)
Female 47 (47.5) 46 (46.0)
Age, mean (SD), years 61.8 (8.9) 63.5 (8.2)
COPD diagnosis, mean (SD), years 7.4 (5.2) 9.4 (7.9)
Pre-bronchodilator
Mean (SD) FEV1, L 1.241 (0.451) 1.242 (0.504)
Mean (SD) FEV1/FVC, % 49.571 (11.562) 48.673 (12.144)
Mean (SD) % of predicted
normal FEV1
44.904 (13.908) 46.010 (14.678)
Post-bronchodilator
Mean (SD) FEV1, L 1.417 (0.494) 1.439 (0.530)
Mean (SD) FEV1 change from
pre-bronchodilator, L 0.177 (0.158) 0.197 (0.158)
Mean (SD) FEV1/FVC, % 50.224 (11.133) 49.354 (11.460)
Mean (SD) % of predicted
normal FEV1
51.368 (15.009) 53.242 (14.706)
GOLD stage, n (%)
2 51 (51.5) 56 (56.0)
3 39 (39.4) 39 (39.0)
4 9 (9.1) 5 (5.0)
BMI, mean (SD), kg/m2 28.7 (7.7) 27.8 (7.2)
Current smoker, n (%) 60 (60.6) 43 (43.0)
Smoking history, mean (SD), pack-years 54.9 (24.8) 51.2 (26.7)
BMI = body mass index; COPD = chronic obstructive pulmonary disease;
FEV1 = forced expiratory volume in 1 sec; FVC = forced vital capacity;
GOLD = Global initiative for chronic Obstructive Lung Disease;
SD = standard deviation.
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ary efficacy variables included FEV1 measurements at
individual time points over 24 h after 6 weeks of treat-
ment, FEV1 AUC from 0 to 3 h (AUC0–3) response,
peak FEV1 response, and trough FEV1 response. Corre-
sponding FVC responses after 6 weeks were also mea-
sured. Safety end points included adverse events (AEs),
vital signs, blood chemistry, and electrocardiogram.
Assessments
All qualifying pulmonary function tests (PFTs) (FEV1 and
FVC) were conducted during the screening visit, and
were started at approximately the same time of day for
each patient (ie, between 7:00 AM and 9:00 AM; ±30 min
maximal difference between the start of the tests on visit
2 and those conducted on subsequent test days). At
the start of each treatment period, PFTs were con-
ducted 60 min and 10 min before administration of
the morning dose of study drug and at 30 min, 1, 2,
and 3 h post-morning dose. Further PFTs were carried
out at the end of each treatment period 30 min before
administration of the morning dose and at 30 min, 1,
2, 3, 4, 6, 8, 10 h, 11 h 50 min, 12 h 30 min, and 13,
14, 22, 23 h, and 23 h 50 min post-morning dose of
study drug (the evening dose of study drug was ad-
ministered 12 h after the morning dose). Patients were
required to stay overnight in the clinic or at a nearby
hotel to ensure the quality and timing of PFTs at 22,
23 h, and 23 h 50 min post-dose on the second day of
the 24-h PFT visit. All spirometric maneuvers were
conducted in triplicate and performed according to
American Thoracic Society/European Respiratory Society
criteria (Miller et al. 2005). Daily trial medication and
rescue medication use were recorded in paper diaries.
Safety end points were assessed in all patients who
received at least one dose of study drug. All AEs, ir-
respective of causality, were monitored and recorded
at each visit.
Statistical analysis
A sample size of 80 randomized patients provided 90%
power to detect a treatment difference between oloda-
terol and placebo of 60 mL in FEV1 AUC0–12 and 51 mL
in FEV1 AUC12–24, based on an estimated standard devi-
ation of 0.160 and 0.140 L, respectively. The conserva-
tive randomized discontinuation was estimated to be
20%, resulting in 100 patients randomized.
The primary and secondary efficacy end points were
based on the full analysis set, which included all pa-
tients with baseline data and evaluable post-dosing
data for at least the first co-primary end point. Both
primary and secondary end points were analyzed
using a mixed-effects repeated measures model with
terms for “center”, “patient within center”, “treatment”, and“period”. Analyses included the fixed categorical effects of
“treatment”, “period”, and “random effect for patient”.
Compound symmetry covariance structure was used to
model within-patient variation. Analyses of AEs, laboratory
data, and vital signs were descriptive in nature.
Results
Patient disposition and baseline characteristics
A total of 199 patients were randomized to treatment in
both studies (Figure 2): 99 in study 1222.24 and 100
in study 1222.25. All patients were randomized be-
tween August 31 and September 15, 2009 (1222.24),
and September 01 to 15, 2009 (1222.25) at different US
sites involved in each study. All randomized patients
received at least one dose of study drug and the major-
ity (86%) completed all four treatment periods. There
was a total of 24 occurrences of a patient discontinuing
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study 1222.25), primarily due to AEs. Patients who dis-
continued from a treatment period were permitted to
remain in the study and continue into the next treat-
ment period. Patient demographics and baseline disease
characteristics were well balanced across the studies
(Table 1).
Efficacy
The FEV1 time profiles for both doses of olodaterol were
similar over 24 h (Figure 3). Mean FEV1 increased to
near-maximal within 30 min and was sustained over
the full 24-h post-dose evaluation period. Following
the morning dose of formoterol, mean FEV1 also in-
creased within 30 min and was comparable to both
doses of olodaterol 0 to 3 h post-dose. The FEV1 time
profile of formoterol intersected with the FEV1 time
profile of both olodaterol doses at 4 h and was lower
than the FEV1 responses observed with both doses of
olodaterol 4 to 12 h post-dose. The evening dose of
formoterol resulted in an additional increase in ad-
justed mean FEV1, which was sustained over the 12 to
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Figure 3 FEV1 24-h profiles of olodaterol 5 and 10 μg and formoterol
and (b) study 1222.25. BID = twice daily; FEV1 = forced expiratory volumePrimary and key secondary end points
In both studies, both primary end points of FEV1 AUC0–12
and AUC12–24 responses and the key secondary end
point of FEV1 AUC0–24 response were significantly im-
proved with olodaterol 5 μg QD, olodaterol 10 μg QD,
and formoterol 12 μg BID compared to placebo (P < .0001)
(Table 2). Pooled data showed no differences between
olodaterol 5 and 10 μg QD compared to formoterol
12 μg BID for the FEV1 AUC0–12 response. However, the
adjusted mean FEV1 AUC12–24 response for formoterol
12 μg BID was significantly greater than olodaterol 5 and
10 μg QD. For both FEV1 AUC0–12 and AUC12–24 re-
sponses, both doses of olodaterol were similar (Table 3).
No statistically significant differences in FEV1 AUC0–24
responses were reported between all three active compar-
ators (Table 3).
Secondary end points
There were statistically significant improvements in the
peak FEV1 response for all active comparators compared
to placebo (P < .0001) (Table 4). Pooled analysis demon-
strated that there were no statistically significant differ-
ences in peak FEV1 responses between the two olodaterol12 16 20
tive to dosing, h
24
12 16 20








Formoterol 12 µg BID
Olodaterol 10 µg
12 μg BID compared to placebo at week 6 in (a) study 1222.24
in 1 sec.
Table 2 Adjusted mean FEV1 AUC0–12, AUC12–24, and AUC0–24 responses (L) compared to placebo after 6 weeks
Treatment Adjusteda mean (95% CI) difference from placebo at 6 weeks
FEV1 AUC0–12 n Adjusted mean (SE) Mean (SE) P value 95% CI
Study 1222.24
Placebo 93 −0.060 (0.020)
Olodaterol 5 μg QD 92 0.088 (0.021) 0.148 (0.018) < .0001 0.113, 0.183
Olodaterol 10 μg QD 91 0.088 (0.021) 0.148 (0.018) < .0001 0.113, 0.183
Formoterol 12 μg BID 90 0.081 (0.021) 0.141 (0.018) < .0001 0.106, 0.177
Study 1222.25
Placebo 91 −0.022 (0.024)
Olodaterol 5 μg QD 92 0.150 (0.024) 0.172 (0.017) < .0001 0.139, 0.205
Olodaterol 10 μg QD 90 0.152 (0.024) 0.174 (0.017) < .0001 0.140, 0.208
Formoterol 12 μg BID 90 0.136 (0.024) 0.158 (0.017) < .0001 0.124, 0.191
FEV1 AUC12–24
Study 1222.24
Placebo 93 −0.123 (0.021)
Olodaterol 5 μg QD 92 −0.014 (0.022) 0.109 (0.019) < .0001 0.073, 0.146
Olodaterol 10 μg QD 91 0.004 (0.022) 0.127 (0.019) < .0001 0.091, 0.164
Formoterol 12 μg BID 90 0.049 (0.022) 0.172 (0.019) < .0001 0.135, 0.209
Study 1222.25
Placebo 91 −0.048 (0.025)
Olodaterol 5 μg QD 92 0.069 (0.025) 0.118 (0.018) < .0001 0.082, 0.154
Olodaterol 10 μg QD 90 0.072 (0.025) 0.120 (0.018) < .0001 0.084, 0.157
Formoterol 12 μg BID 90 0.107 (0.025) 0.155 (0.018) < .0001 0.119, 0.191
FEV1 AUC0–24
Study 1222.24
Placebo 93 −0.092 (0.020)
Olodaterol 5 μg QD 92 0.037 (0.021) 0.128 (0.017) < .0001 0.094, 0.163
Olodaterol 10 μg QD 91 0.046 (0.021) 0.137 (0.017) < .0001 0.103, 0.172
Formoterol 12 μg BID 90 0.065 (0.021) 0.156 (0.018) < .0001 0.122, 0.191
Study 1222.25
Placebo 91 −0.035 (0.024)
Olodaterol 5 μg QD 92 0.110 (0.024) 0.145 (0.016) < .0001 0.114, 0.176
Olodaterol 10 μg QD 90 0.112 (0.024) 0.147 (0.016) < .0001 0.116, 0.179
Formoterol 12 μg BID 90 0.121 (0.024) 0.156 (0.016) < .0001 0.125, 0.187
AUC0–12 = area under the curve from 0 to 12 h; AUC0–24 = area under the curve from 0 to 24 h; AUC12–24 = area under the curve from 12 to 24 h; BID = twice daily;
FEV1 = forced expiratory volume in 1 sec; SE = standard error.
aBased on a mixed effects repeated measures model. The model includes treatment and period as fixed effects and center and patient within center as random
effects, along with compound symmetry as a covariance structure for within−patient variation.
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and 10 μg doses was significantly lower than formoterol
(−0.036 and −0.034 L, respectively). Additionally, signifi-
cant improvements in trough FEV1 and FEV1 AUC0–3 re-
sponses were observed with both doses of olodaterol and
formoterol in comparison to placebo (Table 4).
The corresponding FVC responses after 6 weeks’ treat-
ment with olodaterol 5 and 10 μg QD and formoterol
12 μg BID were consistent with the FEV1 AUC responsesand significantly improved vs placebo (Additional file 1:
Tables S2–S4). In the pooled analysis, no statistically
significant differences between olodaterol doses were
observed for FVC AUC0–12, FVC AUC12–24, and FVC
AUC0–24. Similar to FEV1 AUC12–24, the adjusted mean
FVC AUC12–24 response for formoterol 12 μg BID was
significantly greater than olodaterol 5 and 10 μg QD
(−0.083 L [P = .0001] and −0.074 L [P = .0008], respectively,
vs formoterol 12 μg BID). There were no other statistically
Table 3 Adjusted mean FEV1 AUC0–12, FEV1 AUC12–24, and FEV1 AUC0–24 responses (L); comparisons across active
treatment arms after 6 weeks (pooled analysis)
Treatment difference
FEV1 AUC0–12 P value FEV1 AUC12–24 P value FEV1 AUC0–24 P value
Mean (SE) Mean (SE) Mean (SE)
Olodaterol 10 μg QD vs 5 μg QD 0.001 (0.012) .9527 0.010 (0.013) .4423 0.005 (0.012) .6474
Olodaterol 10 μg QD vs formoterol 12 μg BID 0.011 (0.012) .3588 −0.040 (0.013) .0024 −0.014 (0.012) .2268
Olodaterol 5 μg QD vs formoterol 12 μg BID 0.011 (0.012) .3876 −0.050 (0.013) .0001 −0.020 (0.012) .0944
AUC0–12 = area under the curve from 0 to 12 h; AUC0–24 = area under the curve from 0 to 24 h; AUC12–24 = area under the curve from 12 to 24 h; BID = twice daily;
FEV1 = forced expiratory volume in 1 sec; QD = once daily; SE = standard error.
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the active treatment groups. FVC AUC0–12, AUC12–24,
AUC0–24, and peak and trough FVC responses are
shown in Additional file 1: Tables S2–S6, respectively.
Safety
Overall, 129 patients (64.8%) reported at least one AE
during the studies. Incidence of AEs across active treat-
ment groups was comparable. A total of 13 patients had
AEs that were considered by the investigator to be
related to study drug. The most frequently reported
treatment-emergent AEs were COPD (17.6%) and upper
respiratory tract infection (9.5%) (Table 5). Investigator-
defined related AEs for each treatment group are shown
in Additional file 1: Table S7. In total, 23 patients across
both studies reported at least one serious AE, with the
most frequently reported being COPD (three patients,
study 1222.24; four patients, study 1222.25). Serious AEs
in each treatment group are shown in Additional file 1:
Table S7. One death in each study was reported: cardio-
respiratory arrest (olodaterol 5 μg, study 1222.24) and re-
spiratory failure (olodaterol 10 μg, study 1222.25). These
were not considered by the investigator to be related to
study treatment.
No changes indicative of an AE were observed for any
laboratory parameters or vital signs with either dose of
olodaterol, or formoterol.
Discussion
These replicate studies were designed to complement
the evidence of long-term efficacy and safety provided
by the pivotal 48-week studies in the olodaterol clin-
ical trial program by evaluating the full 24-h FEV1
time profile of olodaterol 5 and 10 μg QD in compari-
son to placebo and formoterol 12 μg BID after chronic
dosing.
FEV1 AUC0–12 and AUC12–24 were chosen as co-primary
end points to allow a comparison between the different
dosing regimens of olodaterol QD and formoterol BID.
FEV1 AUC0–24 was included as a key secondary end point
as it offered a comparison of the average 24-h FEV1 re-
sponse between the active comparators.This evaluation demonstrated that FEV1 AUC0–12,
AUC12–24, and AUC0–24 responses were all significantly
improved with both doses of olodaterol QD and formo-
terol BID vs placebo. There were distinct differences in
the profiles of olodaterol and formoterol over the 24-h
dosing interval, as might be expected given the different
durations of action and consequent variations in dosing
frequency; it should be noted that the methodology used
likely overestimates the differences between active treat-
ments. Nevertheless, FEV1 AUC0–24, a reflection of the
mean bronchodilator effect over 24 h, was similar for
both doses of olodaterol and formoterol. Similar differ-
ences in the 24-h FEV1 time profiles between QD and
BID muscarinic antagonists have recently been observed
in a trial comparing the 24-h bronchodilatory efficacy of
aclidinium BID vs tiotropium QD in patients with mod-
erate to severe COPD (Beier et al. 2013).
While these replicate studies measured lung function
over a continuous 24-h dosing interval, there was a ne-
cessary pause in testing between 14 and 22 h post-dose
to allow patients to have a relatively full night’s sleep. As
such, it is to be noted that the calculation of FEV1
AUC12–24 in the study assumes a linear slope between
14 and 22 h post-dose for both olodaterol and formo-
terol. The FEV1 time profiles in Figure 3 clearly show a
separation of formoterol and olodaterol as a result of the
second peak for formoterol, 1 to 2 h after the evening
dose. In contrast, between 22 and 24 h post-dose, the
FEV1 time profiles for olodaterol and formoterol have
converged. Due to the necessary pause in lung-function
testing between 14 and 22 h post-dose, to allow patients
to sleep, the precise time point at which this conver-
gence occurred is not known.
The results for all other secondary outcomes supported
those of the primary end points, with FVC responses
mirroring FEV1 outcomes. The inclusion of peak FEV1
AUC0–3 and trough FEV1 measurements (at both ends of
the daily dosing profile) provided further evidence to
confirm the 24-h activity of olodaterol, with the ratio
reflecting the degree of bronchodilation that is main-
tained at the end of the dosing interval in relation to the
peak bronchodilation observed in the first hours after
Table 4 Adjusted mean FEV1 AUC0–3, peak FEV1, and trough FEV1 responses (L) compared to placebo after 6 weeks
Treatment Adjusteda mean (95% CI) difference from placebo at 6 weeks
FEV1 AUC0–3 n Adjusted mean (SE) Mean (SE) P value 95% CI
Study 1222.24
Placebo 93 −0.030 (0.020)
Olodaterol 5 μg QD 92 0.134 (0.021) 0.164 (0.019) < .0001 0.126, 0.201
Olodaterol 10 μg QD 91 0.135 (0.021) 0.164 (0.019) < .0001 0.127, 0.202
Formoterol 12 μg BID 90 0.168 (0.021) 0.198 (0.019) < .0001 0.160, 0.236
Study 1222.25
Placebo 91 0.004 (0.024)
Olodaterol 5 μg QD 92 0.190 (0.025) 0.186 (0.019) < .0001 0.149, 0.223
Olodaterol 10 μg QD 90 0.202 (0.025) 0.198 (0.019) < .0001 0.162, 0.235
Formoterol 12 μg BID 90 0.217 (0.025) 0.213 (0.019) < .0001 0.176, 0.250
Peak FEV1
Study 1222.24
Placebo 93 0.034 (0.022)
Olodaterol 5 μg QD 92 0.208 (0.022) 0.174 (0.020) < .0001 0.135, 0.214
Olodaterol 10 μg QD 91 0.200 (0.022) 0.166 (0.020) < .0001 0.127, 0.206
Formoterol 12 μg BID 90 0.251 (0.022) 0.218 (0.020) < .0001 0.178, 0.257
Study 1222.25
Placebo 91 0.076 (0.026)
Olodaterol 5 μg QD 92 0.268 (0.026) 0.192 (0.019) < .0001 0.154, 0.230
Olodaterol 10 μg QD 90 0.273 (0.026) 0.197 (0.020) < .0001 0.158, 0.235
Formoterol 12 μg BID 90 0.293 (0.026) 0.217 (0.020) < .0001 0.178, 0.255
Trough FEV1
Study 1222.24
Placebo 93 −0.093 (0.023)
Olodaterol 5 μg QD 92 0.012 (0.024) 0.106 (0.021) < .0001 0.064, 0.147
Olodaterol 10 μg QD 91 0.020 (0.024) 0.113 (0.021) < .0001 0.072, 0.155
Formoterol 12 μg BID 90 0.040 (0.024) 0.133 (0.021) < .0001 0.092, 0.175
Study 1222.25
Placebo 91 0.012 (0.030)
Olodaterol 5 μg QD 92 0.109 (0.030) 0.097 (0.026) .0003 0.045, 0.148
Olodaterol 10 μg QD 90 0.115 (0.030) 0.103 (0.026) .0001 0.051, 0.155
Formoterol 12 μg BID 90 0.093 (0.030) 0.080 (0.026) .0026 0.028, 0.132
AUC0–3 = area under the curve from 0 to 3 h; BID = twice daily; FEV1 = forced expiratory volume in 1 sec; QD = once daily; SE = standard error.
aBased on a mixed effects repeated measures model. The model includes treatment and period as fixed effects and center and patient within center as random
effects, along with compound symmetry as a covariance structure for within−patient variation.
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http://www.springerplus.com/content/3/1/419dosing. In addition, all FEV1 and FVC responses observed
were in line with those expected for a patient population
continuing with standard bronchodilation and cortico-
steroid maintenance therapy.
The outcomes from these replicate studies support
those from earlier phase II trials employing similar end
points, which demonstrated that single doses of oloda-
terol 5 and 10 μg QD provided effective and significant
bronchodilation over a 24-h period (Joos et al. 2012;van Noord et al. 2009). Furthermore, the outcomes from
these replicate studies add to the comprehensive set of
evidence for the efficacy and safety of olodaterol QD in
patients with COPD derived from the wider olodaterol
phase III clinical program. A similar 12-h bronchodila-
tion profile for olodaterol was observed in a subset of pa-
tients from two independent, 48-week, pivotal studies of
olodaterol 5 and 10 μg QD in comparison with pla-
cebo (Ferguson et al. 2013). Additionally, outcomes from
Table 5 Frequency of AEs (pooled analysis)
Pooled analysis
Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol 18 μg Total
(n = 190) (n = 188) (n = 187) (n = 186) (n = 199)
Patients with any AE 60 (31.6) 61 (32.4) 64 (34.2) 49 (26.3) 129 (64.8)
Patients with severe AEs 11 (5.8) 9 (4.8) 6 (3.2) 10 (5.4) 28 (14.1)
Discontinuations due to AEs 4 (2.1) 4 (2.1) 3 (1.6) 3 (1.6) 14 (7.0)
COPD 12 (6.3) 10 (5.3) 9 (4.8) 8 (4.3) 35 (17.6)
Upper respiratory tract infection 4 (2.1) 5 (2.7) 7 (3.7) 7 (3.8) 19 (9.5)
Bronchitis 3 (1.6) 7 (3.7) 4 (2.1) 4 (2.2) 14 (7.0)
Cough 1 (0.5) 6 (3.2) 1 (0.5) 4 (2.2) 12 (6.0)
Headache 2 (1.1) 2 (1.1) 5 (2.7) 2 (1.1) 9 (4.5)
Sinusitis 3 (1.6) 1 (0.5) 3 (1.6) 3 (1.6) 9 (4.5)
Urinary tract infection 4 (2.1) 0 4 (2.1) 2 (1.1) 9 (4.5)
Diarrhea 1 (0.5) 0 2 (1.1) 2 (1.1) 5 (2.5)
Nausea 3 (1.6) 1 (0.5) 0 1 (0.5) 5 (2.5)
Muscle spasms 1 (0.5) 1 (0.5) 1 (0.5) 2 (1.1) 5 (2.5)
Chest pain 2 (1.1) 1 (0.5) 2 (1.1) 0 5 (2.5)
Pneumonia 1 (0.5) 0 2 (1.1) 1 (0.5) 4 (2.0)
Respiratory tract congestion 3 (1.6) 0 1 (0.5) 0 4 (2.0)
AE = adverse event; COPD = chronic obstructive pulmonary disease.
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http://www.springerplus.com/content/3/1/419similar phase III, replicate, 6-week studies demonstrated
that olodaterol 5 and 10 μg QD significantly improved
FEV1 AUC0–12 and AUC12–24 responses compared to pla-
cebo, with a 24-h bronchodilator profile comparable to
tiotropium (Lange et al. 2013).
A question that arises from the difference in the
24-h lung-function profiles of olodaterol QD and for-
moterol BID is whether the second evening peak in
FEV1 with formoterol is associated with any improve-
ments in night-time symptoms compared to olodaterol.
This cannot be determined from our studies as no assess-
ment of daytime and night-time symptoms was per-
formed. However, two long-term, 48-week studies within
the olodaterol phase III program were conducted using
the BID comparator formoterol (Koch et al. 2013). Des-
pite the second dose of formoterol being given in the
evening, there were no differences between active treat-
ments in night-time rescue medication usage at any time
point in these studies (Boehringer Ingelheim, data on
file). These data suggest that the evening peak in lung
function with formoterol was not manifested in terms of
advantages in night-time symptomatology.
Treatment with both doses of olodaterol and formo-
terol was well tolerated and incidence of AEs across
treatment groups was comparable with the most com-
monly reported AEs: COPD and upper respiratory tract
infection. In addition, safety outcomes in these studies
were consistent with those reported in the pivotal studies.Conclusions
These data, together with those from the wider phase III
clinical program, provide evidence for the 24-h broncho-
dilator efficacy of olodaterol QD in patients with moder-
ate to very severe COPD, with no differences in efficacy
and tolerability observed between olodaterol 5 and 10 μg
QD. Results from this study support the selection of the
5 μg dose for later use in clinical practice.
Additional file
Additional file 1: Supplementary tables S1 to S7.
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